Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct;187(2):144-156.
doi: 10.1111/bjh.16104. Epub 2019 Aug 2.

The concept of leukaemic stem cells in acute myeloid leukaemia 25 years on: hitting a moving target

Peter Hokland  1 , Petter S Woll  2   3 , Marcus C Hansen  4   5 , Marie Bill  4
Affiliations
Review

The concept of leukaemic stem cells in acute myeloid leukaemia 25 years on: hitting a moving target

Peter Hokland et al. Br J Haematol. 2019 Oct.

Abstract

The concept of leukaemic stem cells (LSCs) was experimentally suggested 25 years ago through seminal data from John Dick's group, who showed that a small fraction of cells from acute myeloid leukaemia (AML) patients were able to be adoptively transferred into immunodeficient mice. The initial estimation of the frequency was 1:250 000 leukaemic cells, clearly indicating the difficulties ahead in translating knowledge on LSCs to the clinical setting. However, the field has steadily grown in interest, expanse and importance, concomitantly with the realisation of the molecular background for AML culminating in the sequencing of hundreds of AML genomes. The literature is now ripe with contributions describing how different molecular aberrations are more or less specific for LSCs, as well as reports showing selectivity in targeting LSCs in comparison to normal haematopoietic stem and progenitor cells. However, we argue here that these important data have not yet been fully realised within the clinical setting. In this clinically focused review, we outline the difficulties in identifying and defining LSCs at the individual patient level, with special emphasis on intraclonal heterogeneity. In addition, we suggest areas of future focus in order to realise the concept as real-time benefit for AML patients.

Keywords: acute myeloid leukaemia; clinical targeting; critical re-evaluation; identification; leukaemic stem cells.

PubMed Disclaimer

References

    1. Abarrategi, A., Foster, K., Hamilton, A., Mian, S.A., Passaro, D., Gribben, J., Mufti, G. & Bonnet, D. (2017) Versatile humanized niche model enables study of normal and malignant human hematopoiesis. Journal of Clinical Investigation, 127, 543-548.
    1. Abelson, S., Collord, G., Ng, S.W.K., Weissbrod, O., Mendelson Cohen, N., Niemeyer, E., Barda, N., Zuzarte, P.C., Heisler, L., Sundaravadanam, Y., Luben, R., Hayat, S., Wang, T.T., Zhao, Z., Cirlan, I., Pugh, T.J., Soave, D., Ng, K., Latimer, C., Hardy, C., Raine, K., Jones, D., Hoult, D., Britten, A., McPherson, J.D., Johansson, M., Mbabaali, F., Eagles, J., Miller, J.K., Pasternack, D., Timms, L., Krzyzanowski, P., Awadalla, P., Costa, R., Segal, E., Bratman, S.V., Beer, P., Behjati, S., Martincorena, I., Wang, J.C.Y., Bowles, K.M., Quiros, J.R., Karakatsani, A., La Vecchia, C., Trichopoulou, A., Salamanca-Fernandez, E., Huerta, J.M., Barricarte, A., Travis, R.C., Tumino, R., Masala, G., Boeing, H., Panico, S., Kaaks, R., Kramer, A., Sieri, S., Riboli, E., Vineis, P., Foll, M., McKay, J., Polidoro, S., Sala, N., Khaw, K.T., Vermeulen, R., Campbell, P.J., Papaemmanuil, E., Minden, M.D., Tanay, A., Balicer, R.D., Wareham, N.J., Gerstung, M., Dick, J.E., Brennan, P., Vassiliou, G.S. & Shlush, L.I. (2018) Prediction of acute myeloid leukaemia risk in healthy individuals. Nature, 559, 400-404.
    1. Ailles, L.E., Gerhard, B. & Hogge, D.E. (1997) Detection and characterization of primitive malignant and normal progenitors in patients with acute myelogenous leukemia using long-term coculture with supportive feeder layers and cytokines. Blood, 90, 2555-2564.
    1. Aiuti, A., Webb, I.J., Bleul, C., Springer, T. & Gutierrez-Ramos, J.C. (1997) The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. Journal of Experimental Medicine, 185, 111-120.
    1. Alexander, T.B., Lacayo, N.J., Choi, J.K., Ribeiro, R.C., Pui, C.H. & Rubnitz, J.E. (2016) Phase I study of selinexor, a selective inhibitor of nuclear export, in combination with fludarabine and cytarabine, in pediatric relapsed or refractory acute leukemia. Journal of Clinical Oncology, 34, 4094-4101.

MeSH terms

LinkOut - more resources